Tenatoprazole is a proton pump inhibitor drug candidate that was undergoing clinical testing as a potential treatment for reflux oesophagitis and peptic ulcer as far back as 2003. The compound was invented by Mitsubishi Tanabe Pharma and was licensed to Negma Laboratories
Mitsubishi reported that tenatoprazole was still in Phase I clinical trials in 2007 and again in 2012. Tenatoprazole has an imidazopyridine ring in place of the benzimidazole moiety found in other proton pump inhibitors and has a half-life about seven times longer than other PPIs.
Mechanism of action of Azeloprazole
Tenatoprazole like other drugs of the proton pump inhibitor class works by inhibiting the hydrogen-potassium adenosine triphosphatase(H+/K+ ATPase) acid pump. The term “proton pump inhibitor” comes from the recognition of hydrogen as a single proton. H+/K+ ATPase pumps, found in parietal cells in the stomach, are ultimately responsible for secreting acid into the lumen of the stomach. By inhibiting the secretion of acid, proton pump inhibitors are considered to be useful in the treatment of “acid-related diseases” (e.g. gastroesophageal reflux disease).
Pharmacology of Tenatoprazole
Tenatoprazole like other drugs of the proton pump inhibitor class works by inhibiting the hydrogen-potassium adenosine triphosphatase(H+/K+ ATPase) acid pump. The term “proton pump inhibitor” comes from the recognition of hydrogen as a single proton. H+/K+ ATPase pumps, found in parietal cells in the stomach, are ultimately responsible for secreting acid into the lumen of the stomach. By inhibiting the secretion of acid, proton pump inhibitors are considered to be useful in the treatment of “acid-related diseases” (e.g. gastroesophageal reflux disease).
Medical uses of Azeloprazole
Azeloprazole is an acid-suppressing drug being studied for the treatment of gastroesophageal reflux disease (GERD).
……………………information not available & the product goes to under development, or trial. Further information
References
